Protara Therapeutics Stock Fundamentals
| TARA Stock | USD 2.64 0.11 4.00% |
Protara Therapeutics fundamentals help investors to digest information that contributes to Protara Therapeutics' financial success or failures. It also enables traders to predict the movement of Protara Stock. The fundamental analysis module provides a way to measure Protara Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Protara Therapeutics stock.
At present, Protara Therapeutics' Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Total Other Income Expense Net is expected to grow to about 3.4 M, whereas Depreciation And Amortization is forecasted to decline to about 323.9 K. Protara | Select Account or Indicator |
Protara Therapeutics Company Return On Equity Analysis
Protara Therapeutics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Protara Therapeutics Return On Equity | -0.47 |
Most of Protara Therapeutics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Protara Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Protara Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, Protara Therapeutics has a Return On Equity of -0.4744. This is 98.02% lower than that of the Biotechnology sector and 98.7% lower than that of the Health Care industry. The return on equity for all United States stocks is 53.03% higher than that of the company.
Protara Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Protara Therapeutics's current stock value. Our valuation model uses many indicators to compare Protara Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Protara Therapeutics competition to find correlations between indicators driving Protara Therapeutics's intrinsic value. More Info.Protara Therapeutics is rated fifth in return on equity category among related companies. It is rated fifth in return on asset category among related companies . At present, Protara Therapeutics' Return On Equity is projected to slightly decrease based on the last few years of reporting.Comparative valuation analysis is a catch-all model that can be used if you cannot value Protara Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Protara Therapeutics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Protara Therapeutics' earnings, one of the primary drivers of an investment's value.Protara Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Protara Therapeutics' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Protara Therapeutics could also be used in its relative valuation, which is a method of valuing Protara Therapeutics by comparing valuation metrics of similar companies.Protara Therapeutics is currently under evaluation in return on equity category among related companies.
Protara Fundamentals
| Return On Equity | -0.47 | ||||
| Return On Asset | -0.28 | ||||
| Current Valuation | (28.9 M) | ||||
| Shares Outstanding | 11.43 M | ||||
| Shares Owned By Insiders | 16.59 % | ||||
| Shares Owned By Institutions | 44.16 % | ||||
| Number Of Shares Shorted | 65.23 K | ||||
| Price To Book | 0.51 X | ||||
| EBITDA | (43.27 M) | ||||
| Net Income | (40.42 M) | ||||
| Cash And Equivalents | 98.46 M | ||||
| Cash Per Share | 8.74 X | ||||
| Total Debt | 5.47 M | ||||
| Debt To Equity | 0.05 % | ||||
| Current Ratio | 28.94 X | ||||
| Book Value Per Share | 6.01 X | ||||
| Cash Flow From Operations | (37.56 M) | ||||
| Short Ratio | 0.80 X | ||||
| Earnings Per Share | (3.57) X | ||||
| Target Price | 27.0 | ||||
| Number Of Employees | 26 | ||||
| Beta | 1.88 | ||||
| Market Capitalization | 31.21 M | ||||
| Total Asset | 78.95 M | ||||
| Retained Earnings | (200.38 M) | ||||
| Working Capital | 62.56 M | ||||
| Net Asset | 78.95 M |
About Protara Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Protara Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Protara Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Protara Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Total Revenue | 0.00 | 0.00 | |
| Cost Of Revenue | 341 K | 432.7 K | |
| Stock Based Compensation To Revenue | 0.14 | 0.13 | |
| Sales General And Administrative To Revenue | 1.25 | 1.11 | |
| Research And Ddevelopement To Revenue | 1.96 | 1.74 | |
| Capex To Revenue | (0.02) | (0.02) | |
| Revenue Per Share | 34.63 | 30.78 | |
| Ebit Per Revenue | (2.31) | (2.43) |
Currently Active Assets on Macroaxis
When determining whether Protara Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Protara Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Protara Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Protara Therapeutics Stock:Check out Protara Therapeutics Piotroski F Score and Protara Therapeutics Altman Z Score analysis. For information on how to trade Protara Stock refer to our How to Trade Protara Stock guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Complementary Tools for Protara Stock analysis
When running Protara Therapeutics' price analysis, check to measure Protara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protara Therapeutics is operating at the current time. Most of Protara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protara Therapeutics' price. Additionally, you may evaluate how the addition of Protara Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |
Is Protara Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Protara Therapeutics. If investors know Protara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Protara Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.57) | Return On Assets (0.28) | Return On Equity (0.47) |
The market value of Protara Therapeutics is measured differently than its book value, which is the value of Protara that is recorded on the company's balance sheet. Investors also form their own opinion of Protara Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Protara Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Protara Therapeutics' market value can be influenced by many factors that don't directly affect Protara Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Protara Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Protara Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Protara Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.